APA (7th ed.) Citation

Zhang, C., Chen, J., Wu, H., Wang, J., Gao, L., Zhao, J., . . . Shi, Y. (2024). Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial. Cancer pathogenesis and therapy, 2(4), 268-275. https://doi.org/10.1016/j.cpt.2024.02.001

Chicago Style (17th ed.) Citation

Zhang, Changgong, et al. "Efficacy and Safety of Anlotinib Plus Penpulimab as Second-line Treatment for Small Cell Lung Cancer: A Multicenter, Open-label, Single-arm Phase II Trial." Cancer Pathogenesis and Therapy 2, no. 4 (2024): 268-275. https://doi.org/10.1016/j.cpt.2024.02.001.

MLA (9th ed.) Citation

Zhang, Changgong, et al. "Efficacy and Safety of Anlotinib Plus Penpulimab as Second-line Treatment for Small Cell Lung Cancer: A Multicenter, Open-label, Single-arm Phase II Trial." Cancer Pathogenesis and Therapy, vol. 2, no. 4, 2024, pp. 268-275, https://doi.org/10.1016/j.cpt.2024.02.001.